Evidence map›Paper›PMID 36010926›Full record

ReviewCancers2022

Nanoscale Zeolitic Imidazolate Framework (ZIF)-8 in Cancer Theranostics: Current Challenges and Prospects.

Hongxin Xie, Xinyu Liu, Zhengrong Huang, Liexi Xu, Rui Bai, Fajian He, Mengqin Wang, Linzhi Han, Zhirong Bao, Yuzhou Wu and 2 more

Abstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Encapsulation of Snail Slime in Metal-Organic Framework ZIF-8.Journal of functional biomaterials · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hongxin XieDepartment of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Xinyu LiuDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhengrong HuangDepartment of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Liexi XuDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Rui BaiDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Fajian HeDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Mengqin WangDepartment of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Linzhi HanDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhirong BaoDepartment of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Yuzhou WuHubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan 430074, China.ORCID 0000-0003-3229-4982
Conghua XieDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.ORCID 0000-0001-6623-9864
Yan GongDepartment of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.ORCID 0000-0002-4805-0459

Funding

Key Research & Development Project of Hubei Province 2020BCA069National Natural Science Foundation of China 81800429National Natural Science Foundation of China 81972852
6 · The paper itself

Abstract

Cancer severely threatens human health and has remained the leading cause of disease-related death for decades. With the rapid advancement of nanomedicine, nanoscale metal-organic frameworks are believed to be potentially applied in the treatment and biomedical imaging for various tumors. Zeolite imidazole framework (ZIF)-8 attracts increasing attention due to its high porosity, large specific surface area, and pH-responsiveness. The designs and modifications of ZIF-8 nanoparticles, as well as the strategy of drug loading, demand a multifaceted and comprehensive understanding of nanomaterial features and tumor characteristics. We searched for studies on ZIF-8-based nanoplatforms in tumor theranostics on Web of Science from 2015 to 2022, mainly focused on the research published in the past 3 years, summarized the progress of their applications in tumor imaging and treatment, and discussed the favorable aspects of ZIF-8 nanoparticles for tumor theranostics as well as the future opportunities and potential challenges. As a kind of metal-organic framework material full of potential, ZIF-8 can be expected to be combined with more therapeutic systems in the future and continue to contribute to all aspects of tumor therapy and diagnosis.

Indexed as

combination cancer therapymetal–organic frameworknanomedicinetheranostic nanoplatformzeolite imidazole framework

Identifiers

PMID36010926
PMCPMC9405721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.